Evidence map›Paper›PMID 41403945›Full record

ArticleFrontiers in immunology2025

Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome.

Christian W Keller, Kerstin Stein, Andreu Vilaseca, Luisa M Villar, Gary Álvarez-Bravo, Maria Protopapa, Josef Shin, Nicolás Fissolo, José Enrique Martínez-Rodríguez, Ana Quiroga-Varela and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Christian W KellerDepartment of Neurology, University Hospital Münster, Münster, Germany.
Kerstin SteinDepartment of Neurology, University Hospital Münster, Münster, Germany.
Andreu VilasecaServei de Neurologia and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Luisa M VillarDepartments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Gary Álvarez-BravoUnit of Neuroimmunology and Multiple Sclerosis of Girona (UNIEMTG), Hospital Universitari de Girona Dr. Josep Trueta & Hospital Santa Caterina, Neurodegeneration & Neuroinflammation group, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), Salt, Spain.
Maria ProtopapaDepartment of Neurology, Research Center for Immunotherapy (FZI) and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (Rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Josef ShinDepartment of Neurology, Research Center for Immunotherapy (FZI) and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (Rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Nicolás FissoloServei de Neurologia and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
José Enrique Martínez-RodríguezNeurology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Ana Quiroga-VarelaRed de Enfermedades Inflamatorias, Carlos III Health Institute, Madrid, Spain.
Alexis García-SarreónUnit of Neuroimmunology and Multiple Sclerosis of Girona (UNIEMTG), Hospital Universitari de Girona Dr. Josep Trueta & Hospital Santa Caterina, Neurodegeneration & Neuroinflammation group, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), Salt, Spain.
Lucía GutiérrezDepartment of Neurology, University Hospital Münster, Münster, Germany.
Luciana MidagliaServei de Neurologia and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Xavier MontalbanServei de Neurologia and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jan D LünemannDepartment of Neurology, University Hospital Münster, Münster, Germany.
Manuel ComabellaServei de Neurologia and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: B cells play a central role in multiple sclerosis (MS) pathogenesis, yet their activation profiles during the earliest disease stages remain incompletely characterized. We aimed to investigate the expression of the activation markers CD40 and CD71 across peripheral B cell subsets in individuals with radiologically isolated syndrome (RIS), and compare them to those with clinically isolated syndrome or MS (CIS/MS) and healthy controls (HC). Methods: Peripheral blood cells from individuals with RIS (n=21), CIS/MS (n=15), and HC (n=15) were analyzed by flow cytometry. CD40 and CD71 expression was assessed across major B cell subsets. Epstein-Barr virus (EBV) serologies were measured to explore associations with activation marker expression. Results: CD40 expression was reduced on transitional, naïve, B cell subsets in RIS compared to CIS/MS and HC (p<0.001). CD71 expression remained stable across groups. CD40 expression was preserved in plasmablasts and regulatory B cells. No significant associations were observed between CD40 levels and EBV antibody titers. Discussion: In this cross-sectional cohort, CD40 expression was lower on transitional, naïve, and memory B cell subsets in RIS compared to CIS/MS and HC, whereas plasmablasts and regulatory B cells were comparable. This pattern is consistent with an altered costimulatory state in early, asymptomatic disease and warrants longitudinal studies to determine its clinical relevance.

Indexed as

B-Lymphocyte SubsetsCD40 AntigensDemyelinating DiseasesMultiple SclerosisAdultAntigens, CDBiomarkersCross-Sectional StudiesEpstein-Barr Virus InfectionsFemaleHerpesvirus 4, HumanHumansMaleMiddle AgedReceptors, TransferrinYoung AdultAntigens, CDBiomarkersCD40 AntigensCD71 antigenReceptors, TransferrinB cellsbiomarkersCD40multiple sclerosisradiologically isolated syndrome

Identifiers

PMID41403945
PMCPMC12702762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.